Study #2020-0210
A phase I-II, open label study evaluating the safety and efficacy of alisertib and pembrolizumab in patients with Rb-deficient head and neck squamous cell carcinomas
MD Anderson Study Status
Not Accepting
Treatment Agent
Alisertib, Pembrolizumab
Description
This phase I/II trial investigates the best dose and effect of alisertib in combination with pembrolizumab in treating patients with Rb-deficient head and neck squamous cell cancer. Alisertib may help block the growth of cancer.. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving alisertib in combination with pembrolizumab may help control Rb-deficient head and neck squamous cell cancer. HPV positive head and neck cancers are Rb-deficient.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Head and Neck Squamous Cell Carcinoma, Malignant Solid Neoplasm
Study phase:
Physician name:
Faye Johnson
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-844-829-9300
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.